Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NH2H
|
|||
| Drug Name |
Pyrrolo-pyrimidine derivative 5
|
|||
| Synonyms |
PMID27646564-Compound-7-3
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
NERVIANO MEDICAL SCIENCES S.R.L
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H15F4N5O
|
|||
| Canonical SMILES |
C1CC1NC(=O)C2=CC(=C(C=C2)F)C#CC3=CN(C4=NC=NC(=C34)N)CC(F)(F)F
|
|||
| InChI |
1S/C20H15F4N5O/c21-15-6-3-12(19(30)28-14-4-5-14)7-11(15)1-2-13-8-29(9-20(22,23)24)18-16(13)17(25)26-10-27-18/h3,6-8,10,14H,4-5,9H2,(H,28,30)(H2,25,26,27)
|
|||
| InChIKey |
SHIKADMSFNHXTC-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proto-oncogene c-Ret (RET) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Proto-oncogene c-Ret (RET) | Target's Patent Info | [1] | |
| KEGG Pathway | Endocytosis | |||
| Pathways in cancer | ||||
| Thyroid cancer | ||||
| Central carbon metabolism in cancer | ||||
| Pathway Interaction Database | Signaling events regulated by Ret tyrosine kinase | |||
| Posttranslational regulation of adherens junction stability and dissassembly | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Dopaminergic Neurogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.